Not admitted · Vague or promotional

Post sharing a two-part Carlat Psychiatry Podcast on what went wrong in the MAPS/Lykos trials reviewed by the FDA Advisory Committee. The author says the MDMA-AT story is not over and recalls that the FDA set a high bar for clozapine (safety monitoring, superiority, treatment-resistant patients).

No entity, observable event, benchmark or threshold can be written from the text and its immediate context. Slogans ('game changer', 'once-in-a-lifetime opportunity', 'favourite stock') and quantifiers with no countable set ('more', 'first', 'all') without a defined set.